Data extraction was carried out on study characteristics, participant demographics, interventions, and outcomes related to weight reduction, metabolic parameters, and side effects
The benefit for GLP-1-associated nausea specifically has not been studied in a controlled trial, but the mechanism (5-HT3 antagonism and gastric prokinetic effects) is consistent with potential benefit
[12, 13] Taken together, these findings establish GLP-1 receptor agonists as among the most effective medical therapies for both diabetes and obesity, driving their rapid and widespread use
These include semaglutide, liraglutide, dulaglutide, and tirzepatide
Both are once-weekly injectable medications, yet they cater to different needs: Mounjaro is primarily approved for treating Type 2 diabetes in adults, while Wegovy is focused on chronic weight management in adults and adolescents aged 12 and older
Patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) should not use this medication